Logo image of ELABS.OL

ELLIPTIC LABORATORIES ASA (ELABS.OL) Stock Fundamental Analysis

OSL:ELABS - NO0010722283 - Common Stock

10.72 NOK
+0.08 (+0.75%)
Last: 9/8/2025, 9:44:29 AM
Fundamental Rating

4

Overall ELABS gets a fundamental rating of 4 out of 10. We evaluated ELABS against 101 industry peers in the Software industry. ELABS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ELABS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ELABS has reported negative net income.
In the past year ELABS has reported a negative cash flow from operations.
ELABS had negative earnings in 4 of the past 5 years.
In the past 5 years ELABS always reported negative operating cash flow.
ELABS.OL Yearly Net Income VS EBIT VS OCF VS FCFELABS.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

ELABS has a worse Return On Assets (-3.99%) than 64.36% of its industry peers.
With a Return On Equity value of -4.38%, ELABS is not doing good in the industry: 60.40% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -3.99%
ROE -4.38%
ROIC N/A
ROA(3y)-5.97%
ROA(5y)-5.33%
ROE(3y)-6.62%
ROE(5y)-5.96%
ROIC(3y)N/A
ROIC(5y)N/A
ELABS.OL Yearly ROA, ROE, ROICELABS.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

ELABS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELABS.OL Yearly Profit, Operating, Gross MarginsELABS.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

5

2. Health

2.1 Basic Checks

ELABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ELABS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ELABS has been increased compared to 5 years ago.
The debt/assets ratio for ELABS has been reduced compared to a year ago.
ELABS.OL Yearly Shares OutstandingELABS.OL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ELABS.OL Yearly Total Debt VS Total AssetsELABS.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

A Debt/Equity ratio of 0.03 indicates that ELABS is not too dependend on debt financing.
ELABS has a better Debt to Equity ratio (0.03) than 83.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC8.77%
ELABS.OL Yearly LT Debt VS Equity VS FCFELABS.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ELABS has a Current Ratio of 7.85. This indicates that ELABS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 7.85, ELABS belongs to the best of the industry, outperforming 94.06% of the companies in the same industry.
ELABS has a Quick Ratio of 7.85. This indicates that ELABS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ELABS (7.85) is better than 94.06% of its industry peers.
Industry RankSector Rank
Current Ratio 7.85
Quick Ratio 7.85
ELABS.OL Yearly Current Assets VS Current LiabilitesELABS.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.67% over the past year.
ELABS shows a strong growth in Revenue. In the last year, the Revenue has grown by 45.65%.
ELABS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.29% yearly.
EPS 1Y (TTM)41.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
Revenue 1Y (TTM)45.65%
Revenue growth 3Y34.19%
Revenue growth 5Y28.29%
Sales Q2Q%-27.4%

3.2 Future

The Earnings Per Share is expected to grow by 170.95% on average over the next years. This is a very strong growth
Based on estimates for the next years, ELABS will show a very strong growth in Revenue. The Revenue will grow by 51.54% on average per year.
EPS Next Y595.25%
EPS Next 2Y255.21%
EPS Next 3Y170.95%
EPS Next 5YN/A
Revenue Next Year68.73%
Revenue Next 2Y58.03%
Revenue Next 3Y51.54%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ELABS.OL Yearly Revenue VS EstimatesELABS.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M
ELABS.OL Yearly EPS VS EstimatesELABS.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 1 1.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ELABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 10.62 indicates a reasonable valuation of ELABS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ELABS indicates a rather cheap valuation: ELABS is cheaper than 93.07% of the companies listed in the same industry.
ELABS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.69.
Industry RankSector Rank
PE N/A
Fwd PE 10.62
ELABS.OL Price Earnings VS Forward Price EarningsELABS.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 -60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ELABS is valued a bit more expensive than 63.37% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 58.99
ELABS.OL Per share dataELABS.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ELABS's earnings are expected to grow with 170.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y255.21%
EPS Next 3Y170.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELABS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELLIPTIC LABORATORIES ASA

OSL:ELABS (9/8/2025, 9:44:29 AM)

10.72

+0.08 (+0.75%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)08-28 2025-08-28/bmo
Earnings (Next)N/A N/A
Inst Owners35.11%
Inst Owner ChangeN/A
Ins Owners8.64%
Ins Owner ChangeN/A
Market Cap1.13B
Analysts84.44
Price Target19.38 (80.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-27.98%
Min Revenue beat(2)-45.84%
Max Revenue beat(2)-10.11%
Revenue beat(4)1
Avg Revenue beat(4)-13.8%
Min Revenue beat(4)-45.84%
Max Revenue beat(4)13.5%
Revenue beat(8)2
Avg Revenue beat(8)-19.97%
Revenue beat(12)2
Avg Revenue beat(12)-22.35%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)2.7%
EPS NQ rev (3m)-36.67%
EPS NY rev (1m)-22.86%
EPS NY rev (3m)-22.86%
Revenue NQ rev (1m)4.91%
Revenue NQ rev (3m)-20.82%
Revenue NY rev (1m)-2.52%
Revenue NY rev (3m)-14.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.62
P/S 8.89
P/FCF N/A
P/OCF N/A
P/B 3.69
P/tB 4.8
EV/EBITDA 58.99
EPS(TTM)-0.14
EYN/A
EPS(NY)1.01
Fwd EY9.42%
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS1.21
BVpS2.91
TBVpS2.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.99%
ROE -4.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-5.97%
ROA(5y)-5.33%
ROE(3y)-6.62%
ROE(5y)-5.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.52
Cap/Depr 129.41%
Cap/Sales 23.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.85
Quick Ratio 7.85
Altman-Z N/A
F-Score6
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)167.84%
Cap/Depr(5y)198.62%
Cap/Sales(3y)35.14%
Cap/Sales(5y)37.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
EPS Next Y595.25%
EPS Next 2Y255.21%
EPS Next 3Y170.95%
EPS Next 5YN/A
Revenue 1Y (TTM)45.65%
Revenue growth 3Y34.19%
Revenue growth 5Y28.29%
Sales Q2Q%-27.4%
Revenue Next Year68.73%
Revenue Next 2Y58.03%
Revenue Next 3Y51.54%
Revenue Next 5YN/A
EBIT growth 1Y83.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17528.6%
EBIT Next 3Y678.6%
EBIT Next 5YN/A
FCF growth 1Y57.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.11%
OCF growth 3YN/A
OCF growth 5YN/A